A ppropriate treatment of acute myocardial infarction (AMI) can substantially reduce 30-day mortality. 1 However, guideline-based therapies are not uniformly applied, 2 and there is much variation in mortality among hospitals. For hospitals to be accountable for the care they provide to patients with AMI, they need to be able to compare their performance. In an increasingly competitive medical environment, information about outcomes holds substantial interest for patients, healthcare providers, employers, and healthcare plans.
An impediment to the reporting of outcomes is the challenge of comparing institutions with patients who have different risk profiles. Without adjustment for these baseline differences, comparisons of crude mortality rates favor hospitals that admit the lowest-risk patients. Meaningful evaluations of hospital performance need to consider baseline differences in patient characteristics that could confound comparisons among them.
One approach to facilitate the comparison of hospitals is to use a mathematical model based on patient characteristics to predict mortality and calculate a standardized mortality ratio (SMR), the ratio of the observed mortality of a hospital divided by its predicted mortality. Hospitals can be compared more meaningfully by use of SMRs because these ratios take into account differences in baseline patient characteristics. There is, however, a paucity of information to guide the choice of risk-adjustment model to predict mortality. Many studies have identified prognostic factors for patients with AMI, 3 and some studies have promoted specific predictive models. [3] [4] [5] [6] [7] Complex risk-adjustment models may be preferred by some clinicians because of the breadth of information they include, but extensive data collection efforts can be costly. An ideal model would balance parsimony and ease of data collection with predictive ability.
The objective of this study was to develop a model based on a small number of easily abstracted variables that would accurately predict short-term mortality among patients with AMI. In addition, we sought to compare our model with other published models with respect to discriminant ability, calibration, and hospital ranking. To address these objectives, this study was conducted as part of the Cooperative Cardiovascular Project (CCP), a Health Care Financing Administration initiative to improve the quality of care for Medicare beneficiaries with AMI. 2 
Methods

Data Sources
The CCP
The CCP database has been described previously. 2 In brief, it includes Ͼ200 000 patients hospitalized across the country with a principal discharge diagnosis of AMI (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] 410) from 1994 to 1995. Trained technicians abstracted predefined demographic, clinical, and treatment variables from copies of the hospital records and entered them directly into a computer database using interactive software. For all CCP samples, Ͼ3000 records were reabstracted, with overall variable agreement of Ϸ95%.
Medicare Enrollment Database
The Medicare Enrollment Database contains accurate records of the vital status of Medicare beneficiaries, 8 but entries from the Social Security records include unverified dates of death recorded as the last day of the month when the exact date from a death certificate was unavailable. We eliminated cases with unverified days of death from the mortality analysis if mortality could not be classified with certainty at the time of evaluation, as described in an earlier report. 7 We found unverified days of death for 325 patients in our sample (Ϸ0.2% of such patients or 0.8% of deaths).
Study Sample
The overall study sample was restricted to patients Ն65 years of age who had confirmed AMI, as previously reported, 2 and who were not received in transfer from another institution. To avoid counting patients more than once, we included only a patient's first confirmed AMI hospitalization in the CCP.
Derivation and Validation of Predictive Model
Candidate Predictor Variables
From our review of the medical literature and clinical experience, we selected candidate predictor variables that described demographic and clinical characteristics of the patients. These variable domains (and the specific variables) included the following: demographic characteristics (age, sex, and race), medical history (angina, hypertension, diabetes, active ulcer disease, bleeding disorder, internal bleeding, bypass surgery, heart failure or pulmonary edema, chronic obstructive pulmonary disease, cigarette smoker, stroke, AMI, angioplasty, and trauma in the past month), functional status (mobility, urinary continence, and dementia), clinical presentation and severity variables (systolic and diastolic blood pressures, pulse, respiratory rate, temperature, presence of chest pain, time since chest pain started, hemorrhage, cardiac arrest, gallop rhythm or S 3 , rales, heart failure or pulmonary edema, cardiomegaly, height, and weight), initial laboratory results (albumin, serum urea nitrogen, creatinine, hematocrit, sodium, and white blood count), and first ECG (left bundle-branch block, pacemaker rhythm, right bundle-branch block, ST-segment elevation, transmural MI, ventricular tachycardia, atrial fibrillation [AF]/flutter, second-or third-degree heart block, evidence of old infarction, and location of AMI). We did not include shock because of concerns that it would be susceptible to intentional manipulation.
Model Development and Validation
We defined a derivation sample that randomly included half of the hospitals in the study sample. In this derivation set, we performed iterations of logistic regression models with 30-day mortality as the dependent variable, gradually reducing the number of independent predictors. We began with all 73 candidate predictors with their associated dummy variables. When variables with missing observations were included in or removed from multivariate models, dummy variables indicating the presence of missing values (yes/no) were also added or removed. We then selected 40 variables with a significance level of PϽ0.001 in the logistic regression. To identify the most influential variables, the model was further restricted to 23 variables with a Wald 2 value Ͼ50. At this point, we created composite variables in which related variables had similar ORs (eg, we combined anterior MI location with lateral MI location). We repeated the logistic regression, selecting 7 variables with a Wald 2 value Ͼ300. Although this threshold is arbitrary, it allowed selection of variables with strong clinical associations to 30-day mortality.
Missing Data and Extreme Values
Missing observations exceeded 5% for the following candidate predictor variables: angina, time since chest pain started, evidence of heart failure or pulmonary edema on chest x-ray, location of AMI, ventricular tachycardia, height, weight, albumin, AF/flutter, heart block on ECG, left or right bundle-branch block, and paced rhythm. Values for continuous variables outside the following ranges were considered implausible and set to missing: respiratory rate Ͼ80 breaths per minute, systolic blood pressure Ͼ300 mm Hg, diastolic blood pressure Ͼ150 mm Hg, serum urea nitrogen Ͼ200 mg/dL, creatinine Ͼ25 mg/dL, and albumin Ͼ20 mg/dL. We replaced values outside the following ranges with either minimum or maximum values: systolic blood pressure (70 to 300 mm Hg) and creatinine (0.6 to 2.5 mg/dL).
Approximately 2.7% of the sample had missing values for creatinine and white blood cell count, and 0.5% had missing values for systolic blood pressure (Appendix A). Because missing systolic blood pressure was associated with higher mortality (PϽ0.001), possibly representing situations in which patients were unstable, we replaced missing values with minimum values (70 mm Hg). Missing observations for creatinine and white blood cell count were replaced with median values. Observations with missing values for MI location and radiographic evidence of heart failure were set to null. Alternative methods for controlling missing values, such as including dummy variables indicating missing observations or restricting the analysis to observations without any missing values, did not substantially affect model estimates, calibration, or our conclusions.
Model Comparison
We compared the new model with the following published AMIspecific models of 30-day mortality: the CCP-pilot model, 7 the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial (GUSTO-I) model, 4 the Medicare Mortality Predictor System (MMPS) model, 5 an ICD-9 code model, 6 and 2 models from the California Hospital Outcomes Project 9 ( Table 1 ). The CCP-pilot model and the ICD-9 model were not modified. The GUSTO-I model included all the demographic and clinical variables, but the type of thrombolytic therapy was not included because this sample was not restricted to patients who received it. Our version of the MMPS did not include values for serum potassium in the APACHE II 10 score, which were not abstracted for the CCP. The California risk-adjustment models included 2 ICD-9 -based models: model A (CA-A), which included The following variables only occur in 1 model. *Cardiomegaly, respiratory rate, albumin, ECG reading (yes/no), no MI on ECG, or conduction disturbance (AF, heart block, hemiblock, left bundle-branch block, right bundle-branch block, or significant arrhythmia).
†Smoking status, rales, choice of thrombolytic therapy, time to thrombolytic therapy. ‡DNR (do not resuscitate), APACHE II score (temperature, systolic blood pressure, diastolic blood pressure, heart rate, respiratory rate, oxygenation, arterial pH level, sodium, creatinine, hematocrit, white blood cell count, motor status, verbal status, eye movement, age, and comorbid conditions [hepatic failure, lymphoma, leukemia, immunosuppression, or cirrhosis]).
§Pulmonary disease, arthritis, peripheral vascular disease, thyroid disease, neurological disorders, dementia, psychoses, paralysis, alcohol/drug abuse, connective tissue disease, liver disease, lung disease, bowel disease, mental retardation, chronic angina, arrhythmias, urinary tract infection, unstable angina, fluid disorder, endocarditis, pneumonia, hypotension, conduction disorders, syncope, gastrointestinal bleeding, ulcers, neurotic disorders, sepsis, coagulation disorders, prosthetic valves, diabetic coma, ruptured aneurysms.
Weeks between AMI admission and most recent prior admission. ¶Admission from emergency room, seizure disorder, aspiration pneumonia, catastrophic sequelae of AMI, stroke on admission, coma, ischemic bowel or liver, renal failure (acute or unspecified), sepsis, complete AV block, or paroxysmal ventricular tachycardia.
#Used to construct Killip class.
risk factors most likely present only at admission, and model B (CA-B), which included additional characteristics believed to be present only at admission but may have occurred during hospitalization. Our versions of CA-A and CA-B did not include source of payment (because all CCP patients were enrolled in Medicare) and year of admission (because CCP admissions were within 1.5 years of each other). All models were recalibrated by use of the validation set.
We used 4 approaches to compare models. First, in a patient-level analysis, we assessed the discriminative ability of each model using analysis of area under the receiver-operating characteristic (AROC) curves. 11 Second, we compared model calibration for each of the models using the Hosmer-Lemeshow 2 statistic. Calibration is a measure of how well a particular model fits the data across a range of patient characteristics. 12 Models with smaller 2 values are less likely to suffer from systemic lack of fit. Third, we determined the correlation of the SMR for each hospital calculated by the different models.
Finally, for each hospital with Ͼ50 cases, we evaluated the degree to which hospital rankings would change when different models were used. We calculated risk-adjusted 30-day mortality rates for each hospital on the basis of each of the models (Appendix B). We assigned each hospital a performance rank on the basis of the decile of risk-adjusted mortality (lowest to highest) for each model. We then determined the agreement in the ranking among the models by classifying the percentage of hospitals that were in a similar decile (defined as the same decile or 1 decile different) by each pair of models. For example, if 1 model classified the hospital in the fifth decile and the other in the sixth or fourth decile, they would be considered to agree. We also assessed the similarity of rankings by comparing each of the models with a ranking based on crude (unadjusted) mortality rates. Table 2 reports the development of the study sample of 161 058 patients. This sample was randomly split by hospital into a derivation set of 82 359 patients and a validation set of 78 699 patients.
Results
Study Sample
New Model Characteristics
In a model with all 73 of the candidate predictor variables, the AROC curve was 0.80. The variables selected for the final model were age, cardiac arrest, anterior or lateral location of myocardial infarction, systolic blood pressure, white blood cell count, serum creatinine, and congestive heart failure ( Table 3) . This model had an AROC curve of 0.77. In the validation cohort, the AROC was also 0.77, indicating good model discrimination (Table 4) . 
Model Comparison
There were 7 variables in our new model, 27 variables in the CCP pilot model, 19 variables in the GUSTO-I model, 31 variables in the MMPS model, 45 variables in the ICD-9 model, 22 variables in the CA-A model for patients with no prior admissions and 16 for patients with prior admissions, and 58 variables in the CA-B model for patients with no prior admission and 45 for patients with prior admissions (Table 1) . The AROC curves for the models were similar, ranging from 0.70 in the ICD-9 model to 0.78 in the CCP pilot model ( Table 4 ). The new model was among the 3 models with the lowest Hosmer-Lemeshow 2 values, performing similarly with the GUSTO-I and CA-A models. The Figure compares the SMR between the different models and the new model. The correlation was highest among the clinically based models.
The agreement in similar rankings by decile for the new model based on risk-adjusted mortality was also highest among the clinically based models (Table 5) . Compared with a ranking based on crude mortality rates, only 38.3% of the hospitals were classified similarly with a ranking based on the new model, 40.6% for the CCP-pilot model, 38.3% for the GUSTO-I model, 45.2% for the MMPS model, 36.0% for the ICD-9 code model, 37.5% for the CA-A model, and 39.5% for the CA-B model.
Discussion
In this study, we developed and validated a simple 7-variable risk model for 30-day mortality after admission for AMI. The model is based on data from medical records obtained from acute-care hospitals throughout the United States. The variables are easy to collect and available at admission. This
SMRs between different models.
parsimonious model yields a predictive performance for 30-day mortality that is comparable to other published clinically based risk indexes that are based on larger numbers of variables. Moreover, the assessment of hospital performance with this model is similar to those obtained by other published models based on clinical information.
The clinically based models produced rankings of hospitals that were more similar to each other than to the administrative code-based models. Among the models tested, the new model had the worst agreement in the ranking of hospitals with the 3 models derived exclusively from administrative data. These models were based on billing codes and may have included information from events that occurred during hospitalization. As a result, the secondary codes may have represented either comorbidities or complications. Previous work has shown that these codes may not commonly agree with documentation in the medical charts. 13 The advantage of the code-based models is that administrative data are readily available on all patients without further data collection required.
The study of risk-adjustment models presents an important challenge. 14 There is no gold standard to compare model performance. We sought to compare published models for their ability to classify hospitals and to determine the SMR. Nevertheless, the fact that the models produce similar results does not ensure that they accurately indicate similar levels of performance. Differences in the characteristics of patients admitted to the various hospitals indicate the need for risk adjustment, as demonstrated by the difference in agreement of the risk-adjustment models with crude mortality rates. However, critics of risk adjustment may be concerned that even the best models cannot explain most of the variation in patient outcome.
None of the models in this study demonstrated perfect agreement in the ranking of hospitals by similar decile. The best agreement achieved between models was 80.3%. Iezzoni and others 15 have expressed concern that the use of different risk-adjustment models can result in different rankings of hospitals. The failing of these models may result from random variation (a particular problem with a small number of cases), imprecision in the measurement of the variables, unmeasured differences among patients, and other uncertainties pertaining to the human condition. Our model is also based on baseline patient characteristics and does not consider treatments that may modify outcome. Although these models provide the best current approach to comparing performance, there is a continuing need to develop better methods of comparison.
When developing a risk-adjustment model, we must consider how variable selection would impact data quality. Because hospitals have an incentive to overstate illness severity, a risk-adjustment model would ideally select clinical measures that could not easily be manipulated. Most of the variables in our new model were not subject to clinical interpretation. Congestive heart failure may have been subject to some variability in clinical interpretation but included radiographic evidence for heart failure in its definition.
This study has several limitations. First, we focused on 30-day mortality. Although short-term mortality is only a single domain with which to evaluate hospitals in terms of performance, it is an outcome that is important to patients and can be measured reliably. Our focus on this outcome is not meant to diminish the importance of other domains that include functioning, satisfaction, and cost. Future studies may address the best approach to evaluating performance across hospitals in these other domains.
Second, the study population included patients who were Ն65 years of age, and the generalizability of the results to younger populations was not explored. However, most patients with AMI are in this older age group. In addition, given the competing risks of older patients, these disease-specific models would be expected to perform less well in a group of older compared with younger patients.
In conclusion, we demonstrate that a simple 7-variable risk model can perform as well as more complex models in comparing hospital mortality rates for AMI. These results can provide a basis for hospitals to develop a simple approach to comparing outcomes for this important diagnosis. 
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